TAM receptors, Phosphatidylserine, inflammation, and Cancer.
Cancer
GAS6
Inflammation
PROS1
Phosphatidylserine
Protein S
PtdSer
TAM receptors
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
27 11 2019
27 11 2019
Historique:
received:
31
07
2019
accepted:
11
10
2019
entrez:
29
11
2019
pubmed:
30
11
2019
medline:
2
10
2020
Statut:
epublish
Résumé
The numerous and diverse biological roles of Phosphatidylserine (PtdSer) are featured in this special issue. This review will focus on PtdSer as a cofactor required for stimulating TYRO3, AXL and MERTK - comprising the TAM family of receptor tyrosine kinases by their ligands Protein S (PROS1) and growth-arrest-specific 6 (GAS6) in inflammation and cancer. As PtdSer binding to TAMs is a requirement for their activation, the biological repertoire of PtdSer is now recognized to be broadened to include functions performed by TAMs. These include key homeostatic roles necessary for preserving a healthy steady state in different tissues, controlling inflammation and further additional roles in diseased states and cancer. The impact of PtdSer on inflammation and cancer through TAM signaling is a highly dynamic field of research. This review will focus on PtdSer as a necessary component of the TAM receptor-ligand complex, and for maximal TAM signaling. In particular, interactions between tumor cells and their immediate environment - the tumor microenvironment (TME) are highlighted, as both cancer cells and TME express TAMs and secrete their ligands, providing a nexus for a multifold of cross-signaling pathways which affects both immune cells and inflammation as well as tumor cell biology and growth. Here, we will highlight the current and emerging knowledge on the implications of PtdSer on TAM signaling, inflammation and cancer.
Identifiants
pubmed: 31775787
doi: 10.1186/s12964-019-0461-0
pii: 10.1186/s12964-019-0461-0
pmc: PMC6881992
doi:
Substances chimiques
Phosphatidylserines
0
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
156Références
J Biol Chem. 2014 Sep 12;289(37):25737-49
pubmed: 25074939
Exp Eye Res. 2005 Nov;81(5):581-91
pubmed: 15949798
Cell Host Microbe. 2013 Aug 14;14(2):136-47
pubmed: 23954153
Invest Ophthalmol Vis Sci. 2009 May;50(5):2427-35
pubmed: 19117932
Mol Cancer. 2018 Jan 31;17(1):20
pubmed: 29386018
J Biol Chem. 2016 May 13;291(20):10586-601
pubmed: 27006397
J Immunol. 1999 Dec 1;163(11):6164-72
pubmed: 10570307
Cancer Res. 2015 Sep 15;75(18):3699-705
pubmed: 26206560
J Clin Invest. 2013 Aug;123(8):3231-42
pubmed: 23867499
J Clin Invest. 1998 Feb 15;101(4):890-8
pubmed: 9466984
Nature. 2001 May 10;411(6834):207-11
pubmed: 11346799
Adv Cancer Res. 2008;100:35-83
pubmed: 18620092
J Immunol. 1999 Mar 15;162(6):3498-503
pubmed: 10092806
Biochem Biophys Res Commun. 1995 Apr 17;209(2):656-63
pubmed: 7537495
Growth Factors. 1994;11(2):125-36
pubmed: 7857657
Biochem Biophys Res Commun. 2008 Nov 7;376(1):70-3
pubmed: 18760998
Stem Cells. 2017 Mar;35(3):679-693
pubmed: 27753164
Clin Cancer Res. 2008 Jan 1;14(1):130-8
pubmed: 18172262
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Immunity. 2013 Jul 25;39(1):160-70
pubmed: 23850380
Front Immunol. 2017 Nov 10;8:1521
pubmed: 29176978
J Cell Biol. 2010 Jun 28;189(7):1059-70
pubmed: 20584912
JCI Insight. 2018 Nov 2;3(21):
pubmed: 30385715
Mol Cell Biol. 2015 Jan;35(1):76-87
pubmed: 25332238
Nature. 2016 Apr 14;532(7598):240-244
pubmed: 27049947
Elife. 2014 Sep 29;3:null
pubmed: 25265470
Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5736-E5745
pubmed: 29871951
Nature. 2014 Mar 27;507(7493):508-12
pubmed: 24553136
J Cell Sci. 2005 Feb 1;118(Pt 3):539-53
pubmed: 15673687
Nat Struct Biol. 2003 Sep;10(9):751-6
pubmed: 12923575
Oncology. 2004;66(6):450-7
pubmed: 15452374
Annu Rev Immunol. 2015;33:355-91
pubmed: 25594431
J Clin Invest. 2018 Jun 1;128(6):2356-2369
pubmed: 29708510
Cold Spring Harb Perspect Biol. 2013 Nov 01;5(11):a009076
pubmed: 24186067
Cancer Res. 2002 Nov 1;62(21):6132-40
pubmed: 12414638
J Biol Chem. 2001 Jan 12;276(2):1071-7
pubmed: 10986279
Cell Growth Differ. 1994 Jun;5(6):647-57
pubmed: 8086340
J Biol Chem. 1996 Nov 22;271(47):30022-7
pubmed: 8939948
Nat Rev Cancer. 2014 Dec;14(12):769-85
pubmed: 25568918
Int J Oncol. 2016 Dec;49(6):2359-2366
pubmed: 27840905
Curr Opin Immunol. 2010 Dec;22(6):740-6
pubmed: 21030229
J Leukoc Biol. 2010 May;87(5):869-75
pubmed: 20103767
J Immunol. 2007 May 1;178(9):5635-42
pubmed: 17442946
Mol Cancer Res. 2017 Jun;15(6):753-764
pubmed: 28184013
Cell Death Differ. 1998 Jul;5(7):551-62
pubmed: 10200509
Cell. 1995 Aug 11;82(3):355-8
pubmed: 7634325
Nat Rev Cancer. 2009 Apr;9(4):239-52
pubmed: 19279573
Cancer Res. 2018 Jun 1;78(11):3002-3013
pubmed: 29531161
Mol Cell Biol. 1991 Oct;11(10):5016-31
pubmed: 1656220
Cancer Cell. 2015 Apr 13;27(4):533-46
pubmed: 25873175
Hum Mol Genet. 2000 Mar 1;9(4):645-51
pubmed: 10699188
J Biol Chem. 1995 Sep 29;270(39):22681-4
pubmed: 7559388
J Clin Invest. 2009 Oct;119(10):2942-53
pubmed: 19729839
Nat Immunol. 2014 Oct;15(10):920-8
pubmed: 25194421
Front Immunol. 2018 Mar 01;9:358
pubmed: 29545796
Oncotarget. 2017 Feb 21;8(8):13986-14002
pubmed: 28118606
Mol Cancer Res. 2017 Dec;15(12):1656-1666
pubmed: 28923840
Adv Exp Med Biol. 2003;533:331-6
pubmed: 15180281
J Immunol. 2012 Oct 1;189(7):3508-20
pubmed: 22942426
Blood. 2010 Mar 18;115(11):2264-73
pubmed: 19965679
Cell. 2007 Dec 14;131(6):1124-36
pubmed: 18083102
J Biol Chem. 2014 Sep 12;289(37):25750-63
pubmed: 25074926
Cell. 1995 Feb 24;80(4):661-70
pubmed: 7867073
Invest Ophthalmol Vis Sci. 2003 Feb;44(2):826-38
pubmed: 12556419
Cancer Res. 1991 Jun 1;51(11):3062-6
pubmed: 2032247
Exp Eye Res. 2001 Oct;73(4):509-20
pubmed: 11825022
Trends Biochem Sci. 2017 Sep;42(9):738-748
pubmed: 28734578
Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13091-6
pubmed: 23878224
Oncogene. 1991 Nov;6(11):2113-20
pubmed: 1834974
Nat Immunol. 2015 Sep;16(9):907-17
pubmed: 26287597
Mol Cancer. 2019 Feb 11;18(1):24
pubmed: 30744655
Ann N Y Acad Sci. 2010 Oct;1209:23-9
pubmed: 20958312
Ann Oncol. 2003 Jun;14(6):898-906
pubmed: 12796028
Adv Exp Med Biol. 2013;991:177-93
pubmed: 23775696
Immunity. 2016 Apr 19;44(4):807-20
pubmed: 27037190
PLoS One. 2015 Jan 24;10(1):e0117787
pubmed: 25617898
Nat Immunol. 2003 Jan;4(1):87-91
pubmed: 12447359
Int J Dev Biol. 2017;61(3-4-5):215-224
pubmed: 28621419
Cancer Immunol Res. 2019 Sep;7(9):1472-1484
pubmed: 31266785
Nature. 1999 Apr 22;398(6729):723-8
pubmed: 10227296
J Biol Chem. 1997 Nov 21;272(47):29411-4
pubmed: 9367994
Clin Cancer Res. 2017 Jun 1;23(11):2713-2722
pubmed: 28476872
Nature. 2013 Dec 19;504(7480):394-400
pubmed: 24270812
Front Mol Neurosci. 2017 May 02;10:124
pubmed: 28512399
Exp Eye Res. 2002 Oct;75(4):391-400
pubmed: 12387786
J Biol Chem. 1994 Apr 8;269(14):10720-8
pubmed: 7511603
Oncotarget. 2015 Oct 13;6(31):30859-75
pubmed: 26356564
Mol Cell Neurosci. 2006 Sep;33(1):96-108
pubmed: 16901715
Oncogene. 1994 Mar;9(3):699-705
pubmed: 8108112
J Biol Chem. 1996 Apr 19;271(16):9785-9
pubmed: 8621659
Cell Syst. 2015 Jul 29;1(1):25-36
pubmed: 26236777
Oncogene. 1994 Sep;9(9):2567-78
pubmed: 8058320
Neuron. 2012 Dec 20;76(6):1123-32
pubmed: 23259948
Cancer Res. 2019 May 15;79(10):2669-2683
pubmed: 30877108